Position in FATE
as of Mar 31, 2026
· filed Apr 15, 2026
Position Value
$21,310
New position
Shares Held
17,759
first reported quarter
Ownership
0.015%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0.ToString("F0")%
Shared 0.ToString("F0")%
None 100.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Merit Financial Group, LLC holds $40,595,069 across 47 Biotechnology names. FATE ranks #46 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | EXEL |
Exelixis, Inc.
|
318,113 | $13,643,864 | |
| 2 | INCY |
Incyte Corp
|
49,484 | $4,657,432 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
10,335 | $4,614,987 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
5,585 | $4,315,191 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
30,594 | $1,728,254 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,903 | $960,514 | |
| 7 | ACAD |
Acadia Pharmaceuticals Inc
|
38,999 | $868,116 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
4,077 | $770,755 |
All Filings in FATE
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $21,310 | 17,759 | Shares | Other | 2026-04-15 | |
| No filing history on record for this holder in this stock. | ||||||